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Abstract
There is unequivocal evidence that high-density lipoprotein (HDL) cholesterol
levels in plasma are inversely associated with the risk of cardiovascular disease
(CVD). Studies of families with inherited HDL disorders and genetic association
studies in general (and patient) population samples have identified a large
number of factors that control HDL cholesterol levels. However, they have not
resolved why HDL cholesterol and CVD are inversely related. A growing body
of evidence from nongenetic studies shows that HDL in patients at increased risk
of CVD has lost its protective properties and that increasing the cholesterol
content of HDL does not result in the desired effects. Hopefully, these insights
can help improve strategies to successfully intervene in HDL metabolism. It is
clear that there is a need to revisit the HDL hypothesis in an unbiased manner.
True insights into the molecular mechanisms that regulate plasma HDL choles-
terol and triglycerides or control HDL function could provide the handholds that
are needed to develop treatment for, e.g., type 2 diabetes and the metabolic
syndrome. Especially genome-wide association studies have provided many
candidate genes for such studies. In this review we have tried to cover the
main molecular studies that have been produced over the past few years. It is
clear that we are only at the very start of understanding how the newly identified
factors may control HDL metabolism. In addition, the most recent findings
underscore the intricate relations between HDL, triglyceride, and glucose metab-
olism indicating that these parameters need to be studied simultaneously.
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Ever since plasma HDL cholesterol concentration was found to be inversely
correlated with the risk of cardiovascular disease (CVD), there has been a strong
interest in the biological mechanisms that can explain this correlation. From a large
number of studies in humans, animals, and tissue culture, it has become clear that
HDL exerts many beneficial functions with prominent roles in cellular cholesterol
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efflux and protection against inflammation. For recent overviews on this topic, see
Luscher et al. (2014) and Rye and Barter (2014).
Paradoxically and not always recognized, however, is that rare inborn errors of
HDL metabolism have illustrated that an almost complete loss of HDL or very high
HDL cholesterol levels do not automatically translate in accelerated or protection
from atherosclerosis, respectively. These observations may be related to the small
numbers of patients available for studies or the absence/presence of concomitant
established risk factors for CVD (such as increased LDL cholesterol, smoking, etc.)
in these individuals. However, these findings by themselves indicate that the
relation of HDL cholesterol with atherosclerosis is not as straightforward as for
LDL cholesterol since in this case increases and decreases are always associated
with increased and decreased risk, respectively.
Genetic approaches are frequently used to study whether changes in plasma
HDL cholesterol concentration affect atherosclerosis. Such studies are conducted in
families, larger patient population samples sharing large-impact mutations in HDL
genes, as well as general population samples. Using candidate gene approaches,
these studies mostly generated contrasting or confusing results [a short summary of
these findings can be found in Chapman et al. (2011)]. Illustrative in this regard
were investigations into variation at the locus encoding for the ATP-binding
cassette transporter A1 (ABCA1). While a complete loss of ABCA1 function
causes near HDL deficiency and often accelerated atherosclerosis in Tangier
patients who are referred to the clinic, studies in general population samples
indicated that ABCA1 gene variation is not necessarily related with plasma HDL
cholesterol concentration and risk of CVD (for review, see Frikke-Schmidt (2011)).
More recently, it has become possible to study the impact of whole-genome
variation on complex diseases which has shed light on our understanding whether
or not genes and their products are related to plasma lipid traits and the risk of CVD.
In this regard, particularly Mendelian randomization studies showed that genetic
variation associated with increased HDL cholesterol does not protect from athero-
sclerosis (Voight et al. 2012). In this case, it concerned a study of common variants
in HDL candidate genes; however, more recently, it was also shown that
low-frequency coding variants (frequencies between 0.1 and 2 %) with relatively
large effects on HDL cholesterol and/or triglycerides were also not associated with
risk for coronary heart disease (Peloso et al. 2014).
These and other studies have placed HDL cholesterol as a pharmaceutical target
under heavy fire especially in the context of several large clinical trials that tested
drugs which increased HDL cholesterol but did reduce atherosclerosis (for reviews
on CETP inhibitors and the use of niacin: Ginsberg and Reyes-Soffer 2013; Rader
and Degoma 2014). While there is still hope for HDL-related interventions as
outlined in a recent review (van Capelleveen et al. 2014), it is clear that there is a
need to revisit the mechanisms that have been put forward to explain the unequivo-
cal relation between HDL cholesterol and risk of CVD in epidemiological studies.
To date, it is repeatedly been pointed out that a focus on the cholesterol content
of HDL should maybe be replaced by a focus on the functions that are associated
with this lipoprotein (Feig et al. 2014; Peloso et al. 2014; Luscher et al. 2014;
Riwanto and Landmesser 2013), but unfortunately, HDL functionality studies have
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thus far not provided a solution to the problems encountered. So far it is not clear
which of HDL properties should and could be targeted. There is evidence for a
focus on HDL as an acceptor of cholesterol (Khera et al. 2011) but later studies
were not able to confirm this (Li et al. 2013a, b). In other words, the association with
CVD risk has only been firmly established for the concentration of cholesterol in
HDL while at the same time there is little evidence of a causal relation between
HDL and CVD (Vergeer et al. 2010). Thus, it is possible that HDL cholesterol is a
proxy for an unknown correlating factor. A renewed focus on the clinical applica-
tion of HDL-based strategies for certain indications on the basis of functional
properties of HDL but also on significant preclinical and clinical data, as was
recently suggested, may hopefully bring relief (Gordts et al. 2013).
In this light, the current chapter focuses on recent studies that have shed new
light on how genes and/or their products affect HDL metabolism. The first section
shortly describes established regulators of HDLmetabolism as a general framework
to help understand the new insights that are described in the second section.
2 Determinants of Plasma HDL Cholesterol Levels
Twin studies have indicated that genetic and environmental parameters equally
contribute to the levels of cholesterol in HDL in the blood (Goode et al. 2007). This
paragraph only shortly describes the major primary and secondary regulators of
HDL cholesterol. It is important to underscore, however, that changes in HDL
cholesterol without changes in other plasma lipid traits are very rare. They are
mostly seen in the context of changes in plasma triglycerides. At the population
level, genome-wide association (GWA) studies have recently confirmed that in
many cases, genetic variation is associated with changes in more than one lipid trait
(Teslovich et al. 2010; Willer et al. 2013).
2.1 Established Primary Regulators of Plasma HDL Cholesterol
For the de novo production of HDL, the small intestine and liver need to produce
apolipoprotein (apo) A-I, ATP-binding cassette protein A1, and lecithin–cholesterol
acyltransferase encoded by the APOAI, ABCA1, and LCAT genes, respectively. When
the production of any of these proteins is attenuated (through functional large-impact
mutations), it immediately translates into a reduction of HDL cholesterol in the
circulation. Other established modulators of HDL are cholesteryl ester transfer
protein (encoded by CETP) and scavenger receptor class B member 1 (SRB1,
encoded by SCARB1). While CETP mediates the transfer of cholesterol ester from
HDL to triglyceride-rich lipoproteins in exchange for triglycerides (thereby
controlling the levels of cholesteryl ester in HDL), SRB1 mediates the selective
cellular uptake of cholesteryl ester in the liver and steroidogenic organs. Figure 1
gives a schematic representation of how the above genes relate to HDL biology.
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2.2 Established Secondary Regulators of Plasma HDL Cholesterol
There are a large number of other factors that affect HDL cholesterol concentration
through modulating the lipolysis of plasma triglycerides [reviewed in Oldoni
et al. (2014)]. Figure 2 only illustrates the major players. Most of these regulate
the activity of lipoprotein lipase (LPL), the sole enzyme capable of breaking down
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Fig. 1 A schematic presentation of factors that control HDL synthesis/binding and/or
HDL-mediated cellular cholesterol homeostasis. The genes in the white boxes encode for key
HDL proteins and enzymes, while the genes in the blue boxes encode for less established (new)
factors that affect HDL metabolism. The roles of the genes in the gray boxes are addressed but
solid evidence has not yet been provided. Abbreviations (proteins encoded by the gene names):
ABCA1 ATP-binding cassette A1, ABCG1 ATP-binding cassette G1, APOAI apolipoprotein A-I,
APOF apolipoprotein F, APOM apolipoprotein M, BMP1 bone morphogenetic protein-1, GLCE
glucuronic acid epimerase, LCAT lecithin–cholesterol acyltransferase, PCPE2 procollagen
C-proteinase enhancer 2, PCYT1 CTP:phosphocholine cytidylyltransferase alpha, SCARB1
encoding for scavenger receptor class B member 1
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(VLDL)) in the circulation. These include genes that encode for LPL’s cofactor
apoC-II (APOCII) as well as apoA-V (APOAV) and inhibitors of the LPL reaction
(APOCIII, ANGPTL3, ANGPTL4). More recently, also GPI-anchored HDL-binding
protein 1 (GPIHBP1) was shown to affect HDL concentration through ultimately its
effect on LPL activity. In addition, hepatic lipase (encoded by LIPC) and endothe-
lial lipase (LIPG) also exert marked effects on HDL cholesterol concentration
mainly through modulating HDL phospholipids and HDL triglycerides,
respectively.
2.3 Missing Heritability
So far, studies of over 40 genes have provided solid evidence that their products
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Fig. 2 A schematic
presentation of factors that
affect HDL through roles in
the conversion and
remodeling of HDL or
through effects on
triglyceride/glucose
metabolism. The genes in the
white boxes encode for
established factors of HDL
conversion/remodeling or
plasma TG hydrolysis. The
genes in the blue boxes
encode for less established
(new) factors. Abbreviations
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may expect these accounting for the estimated 50 % heritability of this trait. This
appears however not to be the case when GWA data are analyzed with the current
statistical methods and datasets: The most recent of meta-analysis indicates that
common genetic variation can only explain 12 % variation of HDL cholesterol
levels while in this study, both variations in established loci as well as newly
identified loci (n¼ 46) were taken into account (Willer et al. 2013). However, in
these calculations, gene–gene and gene–environment interactions are not for. In
addition, the estimated impact of gene variation on the phenotype is based on the
presence and frequency of such variations and these are not constant factors over
the genome.
From a different angle, candidate gene resequencing studies in individuals with
very high or low HDL cholesterol (selected from the general population) have
shown that apparent functional mutations are only found in a few percent of the
cases (Cohen et al. 2004; Haase et al. 2012). Also in individuals that were referred
to the clinic because of extreme levels of HDL cholesterol, resequencing studies of
candidate genes only provided satisfying clues in a minority of the subjects studied
(Candini et al. 2010; Holleboom et al. 2011a, b; Kiss et al. 2007). It may be noted,
however, that most studies conducted thus far focused only on APOAI, LCAT, and
ABCA1 leaving ample room for large-effect variants in other genes. Another study
focused on the origin of high HDL cholesterol levels through sequencing CETP,
LIPG, and GALNT, showed an enrichment of rare coding and splicing mutations in
171 probands (Tietjen et al. 2012). A second study conducted a search for mutations
in 197 lipid-related genes in 80 individuals with extreme HDL cholesterol
phenotypes. The outcome was that multiple mutations in different genes combined
could be responsible for extreme low or high HDL cholesterol levels (Motazacker
et al. 2013). Although a polygenic origin of a complex trait like HDL cholesterol
level appears logical, especially in view of similar studies for plasma triglycerides
(Johansen et al. 2010) or LDL cholesterol (Talmud et al. 2013), this needs to be
confirmed. Larger comprehensive resequencing efforts are warranted to study to
what extent large-impact mutations in established and candidate genes can explain
HDL cholesterol concentration in plasma and how such mutations relate to
CVD risk.
3 Novel Insight into HDL Biology
As indicated above, GWA studies have identified many genomic regions that affect
plasma lipid traits. One of the most famous papers in this regard published in 2010
(Teslovich et al. 2010) already listed 38 loci with HDL cholesterol as lead trait.
Importantly, these and many other GWA studies rediscovered many of the
established “HDL genes” which underscored the potential importance of the
newly identified loci. The most comprehensive meta-analysis in this field of
research to date lists an additional 46 loci that are associated with HDL cholesterol
(Willer et al. 2013). This section tries to capture the novel molecular insights that
have been published over the last few years. Many studies focused on genes that on
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the basis of their proximity to genetic markers in GWA studies were “annotated as
HDL genes.” In addition, other studies (not initiated through genetic insight) which
produced interesting novel insight in HDL biology are shortly discussed.
3.1 De Novo Synthesis of HDL and HDL Binding
3.1.1 Bone Morphogenetic Protein-1 and Procollagen
C-Proteinase Enhancer-2
In 2007, bone morphogenetic protein-1 encoded by BMP-1 (aliases OI13, PCOLC,
PCP, PCP2, TLD) was identified as the metalloproteinase that stimulates the
conversion of newly secreted proapoA-I to its phospholipid-binding form (Chau
et al. 2007). While these results were obtained through in vitro studies, early genetic
association studies showed the possible involvement of procollagen C-proteinase
enhancer-2 (encoded by PCPE2 or PCOLCE2) in modulating HDL cholesterol
levels (Hinds et al. 2004). It was subsequently shown that PCPE2 together with
BMP1 and proapoAI forms a ternary complex and that it is involved in the
regulation of apoA-I posttranslational processing (Zhu et al. 2009). In a later
study, it was shown that Pcpe2 KO mice have strongly increased plasma apoA-I
and HDL cholesterol levels compared with wild-type littermates, regardless of
gender or diet (Francone et al. 2011). Changes in HDL particle size and electropho-
retic mobility observed in Pcpe2 KO mice suggest that the presence of proapoA-I
impairs the maturation of HDL. Although initially picked up by GWA studies,
PCPE2 is not listed in the subsequent respective meta-analyses (Teslovich
et al. 2010; Willer et al. 2013), while BMP1 is also not listed in the latter studies.
So far, the role of BMP1 or PCPE2 in posttranslational processing in humans has
not been reported which in the light of the larger GWA studies performed is now
dependent on the identification of large-impact mutations in individuals with HDL
disorders.
3.1.2 Apolipoprotein M
Originally identified as a protein associated with HDL in 1999 (Xu and Dahlback
1999), apoM was later implicated to play a role in the generation of prebeta-HDL
and cholesterol efflux mediated by HDL (Wolfrum et al. 2005). These results have
recently been supported by evidence in plasma of humans (Plomgaard et al. 2009)
while others have found that human APOM gene variation affects HDL cholesterol
(Park et al. 2013; Aung et al. 2013). Through carrying sphingosine-1-phosphate
with effects on angiogenesis, endothelial cell migration, and inflammation, apoM
(Christoffersen and Nielsen 2013) may be a link to many of the functions that are
attributed to HDL. While there is thus substantial evidence for a role of apoM in
human HDL metabolism, the gene has thus far not been picked up by GWA studies,
while large-impact mutations in this gene have so far not been reported either.
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3.1.3 CTP:Phosphocholine Cytidylyltransferase Alpha (CT Alpha)
Through an interest in the synthesis of phosphatidylcholine (the primary phospho-
lipid in cellular membranes but also of HDL), the group of Dennis Vance studied a
conditional PCTY1 knockout mouse and showed in 2004 that hepatic CTP:
phosphocholine cytidylyltransferase alpha reduces HDL cholesterol and apoA-I
while it also affected VLDL (Jacobs et al. 2004). In 2008, the same investigators
subsequently showed that in hepatocytes isolated from these mice, ABCA1 expres-
sion was reduced. Other findings included normalization of plasma HDL and
VLDL in these mice after adenoviral delivery of CT alpha which clearly implicated
its importance in HDL genesis (Jacobs et al. 2008).
3.1.4 Apolipoprotein F
In proteomic studies, apoF has been identified to be associated with HDL. This
protein is also known as lipid transfer inhibitor protein which is able to inhibit
CETP. Plasma apoF levels were found to be positively associated with HDL
cholesterol in males but not in females (Morton et al. 2008). The Rader group
subsequently showed that overexpression of apoF in mice reduced HDL cholesterol
levels by accelerating clearance from the circulation (Lagor et al. 2009). A later
study showed that a murine apoF knockout model had no substantial effect on
plasma lipid concentrations, HDL size, lipid, or protein (Lagor et al. 2012) although
a reduced ability to promote cholesterol efflux was observed. Until now, no other
studies on apoF have been published.
3.1.5 Glucuronic Acid Epimerase
Through studies in Turkish families, a linkage peak with low HDL cholesterol was
identified on chromosome 15 which was>20 cM wide including the gene encoding
hepatic lipase (LIPC), which has important functions in HDL metabolism. How-
ever, the same investigators suspected that variations in LIPC might not fully
explain this linkage peak and sought additional gene(s) that might contribute to
the peak. This is how they identified GLCE encoding glucuronic acid epimerase, a
heparan sulfate proteoglycan biosynthetic enzyme (Hodoglugil et al. 2011). So far,
no other studies on the role of this enzyme in HDL metabolism have been
conducted while the gene was not found associated with HDL cholesterol levels
in the latest meta-analyses GWA study (Willer et al. 2013).
3.1.6 Beta-Chain of ATP Synthase
In 2003, beta-chain of ATP synthase (encoded by ATPB5), a principal protein
complex of the mitochondrial inner membrane, was surprisingly identified as a
high-affinity HDL receptor for apoA-I receptor with a role in hepatic HDL endocy-
tosis (Martinez et al. 2003). A subsequent study demonstrated a major role of
cytoskeleton reorganization in F(1)-ATPase/P2Y(13)-dependent HDL endocytosis
under the control of the small GTPase RhoA and its effector ROCK I (Malaval
et al. 2009). Others showed that binding of HDL to this receptor triggers the
generation of ADP, which via the activation of the purinergic receptor P2Y13
stimulates the uptake and transport of HDL and initially lipid-free apoA-I by
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endothelial cells (Cavelier et al. 2012). So far, there is no genetic support for the
involvement of beta-chain of ATP synthase and/or P2Y(13), but even mild
mutations could have in the case of ATPB5 lethal consequences. Most recently, it
was reported that there may be a role for beta-chain of ATP synthase in regulating
HDL cholesterol levels as mitochondrial inhibitor factor 1, which inhibits ATPB5
and can be measured in serum, is associated with HDL cholesterol levels (Genoux
et al. 2013).
3.2 HDL Conversion and Remodeling
3.2.1 Angptl Family of Proteins
In the year 2000, ANGPTL4 was identified as a peroxisome proliferator-activated
receptor α response gene (Kersten et al. 2000) while ANGPTL3 is since 2002 known
for its effects on glucose and lipid metabolism through a hypolipidemic mouse
strain (Koishi et al. 2002). Both Angptl3 and Angptl4 are known to inhibit LPL,
thereby having an indirect effect on HDL cholesterol concentration in plasma, but
Angptl3 may also exert direct effects on HDL remodeling through inhibition of
endothelial lipase (Shimamura et al. 2007). In GWA studies published in 2008 and
2010, ANGPTL3 was shown to be associated primarily with triglycerides
(Kathiresan et al. 2008; Teslovich et al. 2010) while more recently it was shown
that human ANGPTL3 deficiency also causes marked reduction in HDL cholesterol
(Musunuru et al. 2010). In 2010, ANGPTL4was reported to be associated with HDL
cholesterol as primary trait (Teslovich et al. 2010) while later on ANGPTL4 variants
were found associated with lower triglycerides and elevated HDL cholesterol
(Romeo et al. 2007). Another study showed that mutant alleles of ANGPTL3 and
ANGPTL4 that were associated with low plasma triglyceride levels interfered either
with the synthesis or secretion of the protein or with the ability of the ANGPTL
protein to inhibit LPL (Romeo et al. 2009). More recently, ANGPTL8 (also known
as betatrophin) was shown to also affect HDL cholesterol through affecting the
activity of Angpl3 (Quagliarini et al. 2012). In addition, low-frequency variants in
ANGPTL8 were shown to affect HDL cholesterol levels (Peloso et al. 2014). For a
recent review on the current eight Angptl proteins, please see Santulli (2014).
3.2.2 Tribbles Homolog 1
Variation at the TRIB1 gene locus has been reported to be associated with
triglycerides (as lead trait), HDL cholesterol, total cholesterol, and LDL cholesterol
(Kathiresan et al. 2008; Teslovich et al. 2010). It is one of the few genes subse-
quently studied in depth in mouse models, in vitro experiments, and further human
genetic association studies. Viral-mediated overexpression in the liver of mice
simultaneously reduced plasma triglycerides and cholesterol of all major
lipoproteins (including HDL). On the other hand, TRIB1 knockout mice showed
elevated levels of triglycerides (Burkhardt et al. 2010) without statistically signifi-
cant effects on HDL cholesterol. These effects were related to an on VLDL
production but it is not known what mechanisms are responsible. Further
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epidemiological studies confirmed that TRIB1 is associated with HDL cholesterol
but interestingly without affecting apoA-I concentration (Varbo et al. 2011). More
recently it was shown that Trib1 is important to adipose tissue maintenance and
suppression of metabolic disorders by controlling the differentiation of tissue-
resident M2-like macrophages (Satoh et al. 2013). In addition, a TRIB1 single-
nucleotide polymorphism was found associated with nonalcoholic fatty liver dis-
ease in humans while the same investigators showed that TRIB1 expression affects
hepatic lipogenesis and glycogenesis through multiple molecular interactions
(including a molecular interaction with MLXIPL or CHREBP, a hepatic lipogenic
master regulator) (Ishizuka et al. 2014). In addition to a role in lipid metabolism,
there is a substantial literature on the role of tribbles in cancer (Liang et al. 2013).
3.2.3 Tetratricopeptide Repeat Domain/Glycogen-Targeting PP1
Subunit G(L)
TTC39B was discovered through GWA studies in 2009 (Kathiresan et al. 2009).
When knocked down in mice (using a viral-mediated strategy), it was shown to
increase HDL cholesterol levels (Teslovich et al. 2010). However, no studies have
since revealed insight into how tetratricopeptide repeat domain 39B may affect
lipid metabolism while another GWA study could not replicate the effect of
TTC39B variation on plasma lipid levels (Dumitrescu et al. 2011).
PPP1R3B was also found to be associated with HDL cholesterol as primary trait
(Teslovich et al. 2010), and in the same paper, viral-mediated overexpression was
shown to reduce HDL cholesterol levels in mice. The gene encoding for glycogen-
targeting PP1 (protein phosphatase 1) subunit G(L) has also been associated with
type 2 diabetes and maturity-onset diabetes of the young but sequence variants at
the PPP1R3B locus were not found to be related to diabetes in mostly Caucasian
families (Dunn et al. 2006). Other studies proposed a role for this gene in inflam-
mation (Dehghan et al. 2011), Alzheimer’s disease (Kamboh et al. 2012), and
hepatic steatosis (Palmer et al. 2013). As for TTC39B, there are no mechanistic
studies that have revealed insight into how PPP1R3B gene products may affect
lipid metabolism.
3.2.4 ppGalNAc-T2
Variation at the GALNT2 locus was also shown to be associated with HDL choles-
terol (Teslovich et al. 2010). Viral-mediated overexpression and knockdown were
shown to decrease and increase HDL cholesterol levels in mice, respectively. In a
later study a rare functional GALNT2 variant, identified in two index cases with very
high HDL cholesterol, was reported to affect HDLmetabolism indirectly via an effect
on the lipolysis of triglycerides (Holleboom et al. 2011a, b). This was suggested to be
in part due to attenuated glycosylation of apoC-III which impaired its capacity to
inhibit LPL in the catabolism of triglycerides. Other investigators reported that
GALNT2 regulates plasma lipid levels through the glycosylation of ANGTPL3,
another inhibitor of the LPL reaction (Schjoldager et al. 2010). Recently,
ppGalNAc-T2 was identified as a novel regulator of insulin signaling (Marucci
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et al. 2013) while there appears to be a role for GALNT2 in hypertension too
(Pendergrass et al. 2013; McDonough et al. 2013).
3.2.5 Glucokinase (Hexokinase 4) Regulator
GCKR (also known as GKRP) encodes for a regulatory protein that inhibits
glucokinase in the liver and pancreatic islet cells by binding non-covalently to
form an inactive complex with the enzyme. This gene is considered a susceptibility
gene candidate for a form of maturity-onset diabetes of the young. GCKR was
picked up in both GWA studies with a focus on plasma lipids but also with type
2 diabetes (van de Bunt and Gloyn 2010). Varbo et al. showed that a GCKR SNP
was associated with increased triglycerides, decreased HDL cholesterol, and
remarkably increased apoA-I (Varbo et al. 2011). Several genetic association
studies have shown that GCKR variants are associated with triglycerides, insulin
resistance (Shen et al. 2013), type 2 diabetes fasting plasma glucose (Li et al. 2013a,
b), hyperglycemia (Stancakova et al. 2012), and nonalcoholic fatty liver disease
(Lin et al. 2014). In 2013, the crystal structure was resolved (Pautsch et al. 2013)
while two potent small-molecule GK–GKRP disruptors were recently reported to
normalize blood glucose levels in several rodent models of diabetes (Lloyd
et al. 2013).
Conclusions and Perspectives
The harvest of screening the most recent published literature for novel HDL
influencing genes is extensive. However, it also shows that there are only very
few mechanistic clues on how “the new kids on the block” (primarily identified
through GWA studies) affect HDL cholesterol or HDL function.
It is interesting that none of the genes encoding for the proteins and enzymes
that have been discussed in the section on the de novo synthesis of HDL are
listed in the current largest GWA studies. This may be surprising in light of the
evidence for the roles of especially bone morphogenetic protein-1, procollagen
C-proteinase enhancer 2, apoM, and CT alpha in HDL metabolism. It shows that
GWA strategies, like any approach, come with limitations. Thus, prioritizing
research interest on the basis of the top ranking GWA hits is not necessarily the
most promising route to go.
In the section on (new) insights in HDL conversion and remodeling, it is clear
that the factors discussed are only indirectly associated with HDL cholesterol
levels through effects on triglyceride and/or glucose metabolism. It may be
noted in this regard that HDL cholesterol was proposed to be the lead trait for
ANGPTL4, TTC39B, PPP1R3B, and GALNT2, in GWA studies which highlights
a need for more comprehensive studies with focus on the mechanistic relations
between HDL cholesterol, triglycerides, and glucose metabolism. Such studies
may need the use of genome-scale metabolic maps.
Finally, this review underlines an urgent need of mechanistic studies. But
where to start? Answering this question is today’s challenge as evidence-based
prioritization tools and high-throughput functional studies are yet to come.
296 J.A. Kuivenhoven and A.K. Groen
Acknowledgments I wish to apologize to colleagues whose work may not be cited in this review:
It remains an attempt to cover the existing literature. This work is supported by Fondation LeDucq
(Transatlantic Network, 2009–2014), the Netherlands CardioVascular Research Initiative
(CVON2012-17; Genius), and the European Union (COST BM0904; Resolve: FP7-305707;
TransCard: FP7-603091–2).
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
References
Aung LH et al (2013) Association of the apolipoprotein M gene polymorphisms and serum lipid
levels. Mol Biol Rep 40(2):1843–1853
Burkhardt R et al (2010) Trib1 is a lipid- and myocardial infarction-associated gene that regulates
hepatic lipogenesis and VLDL production in mice. J Clin Invest 120(12):4410–4414
Candini C et al (2010) Identification and characterization of novel loss of function mutations in
ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein
cholesterol. Atherosclerosis 213(2):492–498
Cavelier C et al (2012) The beta-chain of cell surface F(0)F(1) ATPase modulates apoA-I and
HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol 32(1):131–
139
ChapmanMJ et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in
patients at high risk of cardiovascular disease: evidence and guidance for management. Eur
Heart J 32(11):1345–1361
Chau P et al (2007) Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1
and regulates its activation for lipid binding. Biochemistry 46(28):8445–8450
Christoffersen C, Nielsen LB (2013) Apolipoprotein M: bridging HDL and endothelial function.
Curr Opin Lipidol 24(4):295–300
Cohen JC et al (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol.
Science 305(5685):869–872
Dehghan A et al (2011) Meta-analysis of genome-wide association studies in >80,000 subjects
identifies multiple loci for C-reactive protein levels. Circulation 123(7):731–738
Dumitrescu L et al (2011) Genetic determinants of lipid traits in diverse populations from the
population architecture using genomics and epidemiology (PAGE) study. PLoS Genet 7(6):
e1002138
Dunn JS et al (2006) Examination of PPP1R3B as a candidate gene for the type 2 diabetes and
MODY loci on chromosome 8p23. Ann Hum Genet 70(Pt 5):587–593
Feig JE et al (2014) High-density lipoprotein and atherosclerosis regression: evidence from
preclinical and clinical studies. Circ Res 114(1):205–213
Francone OL et al (2011) Disruption of the murine procollagen C-proteinase enhancer 2 gene
causes accumulation of proapoA-I and increased HDL levels. J Lipid Res 52(11):1974–1983
Frikke-Schmidt R (2011) Genetic variation in ABCA1 and risk of cardiovascular disease. Athero-
sclerosis 218(2):281–282
Genoux A et al (2013) Serum IF1 concentration is independently associated to HDL levels and to
coronary heart disease: the GENES study. J Lipid Res 54(9):2550–2558
Ginsberg HN, Reyes-Soffer G (2013) Niacin: a long history, but a questionable future. Curr Opin
Lipidol 24(6):475–479
Goode EL et al (2007) Heritability of longitudinal measures of body mass index and lipid and
lipoprotein levels in aging twins. Twin Res Hum Genet 10(5):703–711
Beyond the Genetics of HDL: Why Is HDL Cholesterol Inversely Related to. . . 297
Gordts SC et al (2013) Pleiotropic effects of HDL: towards new therapeutic areas for
HDL-targeted interventions. Curr Mol Med 14(4):481–503
Haase CL et al (2012) Population-based resequencing of APOA1 in 10,330 individuals: spectrum
of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS
Genet 8(11):e1003063
Hinds DA et al (2004) Application of pooled genotyping to scan candidate regions for association
with HDL cholesterol levels. Hum Genomics 1(6):421–434
Hodoglugil U et al (2011) Glucuronic acid epimerase is associated with plasma triglyceride and
high-density lipoprotein cholesterol levels in Turks. Ann Hum Genet 75(3):398–417
Holleboom AG et al (2011a) Heterozygosity for a loss-of-function mutation in GALNT2 improves
plasma triglyceride clearance in man. Cell Metab 14(6):811–818
Holleboom AG et al (2011b) High prevalence of mutations in LCAT in patients with low HDL
cholesterol levels in The Netherlands: identification and characterization of eight novel
mutations. Hum Mutat 32(11):1290–1298
Ishizuka Y et al (2014) TRIB1 down-regulates hepatic lipogenesis and glycogenesis via multiple
molecular interactions. J Mol Endocrinol 52(2):145–158
Jacobs RL et al (2004) Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase
alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem
279(45):47402–47410
Jacobs RL et al (2008) Hepatic CTP:phosphocholine cytidylyltransferase-alpha is a critical
predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem
283(4):2147–2155
Johansen CT et al (2010) Excess of rare variants in genes identified by genome-wide association
study of hypertriglyceridemia. Nat Genet 42(8):684–687
Kamboh MI et al (2012) Genome-wide association study of Alzheimer’s disease. Transl Psychia-
try 2:e117
Kathiresan S et al (2008) Six new loci associated with blood low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40(2):189–197
Kathiresan S et al (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat
Genet 41(1):56–65
Kersten S et al (2000) Characterization of the fasting-induced adipose factor FIAF, a novel
peroxisome proliferator-activated receptor target gene. J Biol Chem 275(37):28488–28493
Khera AV et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and athero-
sclerosis. N Engl J Med 364(2):127–135
Kiss RS et al (2007) Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity
of efflux defects. Arterioscler Thromb Vasc Biol 27(5):1139–1145
Koishi R et al (2002) Angptl3 regulates lipid metabolism in mice. Nat Genet 30(2):151–157
LagorWR et al (2009) Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo.
Arterioscler Thromb Vasc Biol 29(1):40–46
Lagor WR et al (2012) The effects of apolipoprotein F deficiency on high density lipoprotein
cholesterol metabolism in mice. PLoS ONE 7(2):e31616
Li H et al (2013a) Association of glucokinase regulatory protein polymorphism with type 2 diabe-
tes and fasting plasma glucose: a meta-analysis. Mol Biol Rep 40(6):3935–3942
Li XM et al (2013b) Paradoxical association of enhanced cholesterol efflux with increased incident
cardiovascular risks. Arterioscler Thromb Vasc Biol 33(7):1696–1705
Liang KL et al (2013) Tribbles in acute leukemia. Blood 121(21):4265–4270
Lin YC et al (2014) Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic
fatty liver disease in obese individuals. Am J Clin Nutr 99(4):869–874
Lloyd DJ et al (2013) Antidiabetic effects of glucokinase regulatory protein small-molecule
disruptors. Nature 504(7480):437–440
Luscher TF et al (2014) High-density lipoprotein: vascular protective effects, dysfunction, and
potential as therapeutic target. Circ Res 114(1):171–182
298 J.A. Kuivenhoven and A.K. Groen
Malaval C et al (2009) RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls
HDL endocytosis in human hepatocytes. Cell Signal 21(1):120–127
Martinez LO et al (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in
hepatic HDL endocytosis. Nature 421(6918):75–79
Marucci A et al (2013) Role of GALNT2 in the modulation of ENPP1 expression, and insulin
signaling and action: GALNT2: a novel modulator of insulin signaling. Biochim Biophys Acta
1833(6):1388–1395
McDonough CW et al (2013) Atenolol induced HDL-C change in the pharmacogenomic evalua-
tion of antihypertensive responses (PEAR) study. PLoS ONE 8(10):e76984
Morton RE et al (2008) Lipid transfer inhibitor protein (apolipoprotein F) concentration in
normolipidemic and hyperlipidemic subjects. J Lipid Res 49(1):127–135
Motazacker MM et al (2013) Evidence of a polygenic origin of extreme high-density lipoprotein
cholesterol levels. Arterioscler Thromb Vasc Biol 33(7):1521–1528
Musunuru K et al (2010) Exome sequencing, ANGPTL3 mutations, and familial combined
hypolipidemia. N Engl J Med 363(23):2220–2227
Oldoni F et al (2014) Mendelian disorders of high-density lipoprotein metabolism. Circ Res 114
(1):124–142
Palmer ND et al (2013) Characterization of European ancestry nonalcoholic fatty liver disease-
associated variants in individuals of African and Hispanic descent. Hepatology 58(3):966–975
Park YJ et al (2013) The APOM polymorphism as a novel risk factor for dyslipidaemia in
rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia.
Clin Exp Rheumatol 31(2):180–188
Pautsch A et al (2013) Crystal structure of glucokinase regulatory protein. Biochemistry 52
(20):3523–3531
Peloso GM et al (2014) Association of low-frequency and rare coding-sequence variants with
blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 94
(2):223–232
Pendergrass SA et al (2013) Phenome-wide association study (PheWAS) for detection of pleiot-
ropy within the population architecture using genomics and epidemiology (PAGE) network.
PLoS Genet 9(1):e1003087
Plomgaard P et al (2009) Apolipoprotein M predicts pre-beta-HDL formation: studies in type
2 diabetic and nondiabetic subjects. J Intern Med 266(3):258–267
Quagliarini F et al (2012) Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl
Acad Sci USA 109(48):19751–19756
Rader DJ, Degoma EM (2014) Future of cholesteryl ester transfer protein inhibitors. Annu Rev
Med 65:385–403
Riwanto M, Landmesser U (2013) High density lipoproteins and endothelial functions: mechanis-
tic insights and alterations in cardiovascular disease. J Lipid Res 54(12):3227–3243
Romeo S et al (2007) Population-based resequencing of ANGPTL4 uncovers variations that
reduce triglycerides and increase HDL. Nat Genet 39(4):513–516
Romeo S et al (2009) Rare loss-of-function mutations in ANGPTL family members contribute to
plasma triglyceride levels in humans. J Clin Invest 119(1):70–79
Rye KA, Barter PJ (2014) Cardioprotective functions of HDLs. J Lipid Res 55(2):168–179
Santulli G (2014) Angiopoietin-like proteins: a comprehensive look. Front Endocrinol (Lausanne)
5:4
Satoh T et al (2013) Critical role of Trib1 in differentiation of tissue-resident M2-like
macrophages. Nature 495(7442):524–528
Schjoldager KT et al (2010) O-glycosylation modulates proprotein convertase activation of
angiopoietin-like protein 3: possible role of polypeptide GalNAc-transferase-2 in regulation
of concentrations of plasma lipids. J Biol Chem 285(47):36293–36303
Shen Y et al (2013) GCKR variants increase triglycerides while protecting from insulin resistance
in Chinese children. PLoS ONE 8(1):e55350
Beyond the Genetics of HDL: Why Is HDL Cholesterol Inversely Related to. . . 299
Shimamura M et al (2007) Angiopoietin-like protein3 regulates plasma HDL cholesterol through
suppression of endothelial lipase. Arterioscler Thromb Vasc Biol 27(2):366–372
Stancakova A et al (2012) Hyperglycemia and a common variant of GCKR are associated with the
levels of eight amino acids in 9,369 Finnish men. Diabetes 61(7):1895–1902
Talmud PJ et al (2013) Use of low-density lipoprotein cholesterol gene score to distinguish
patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
Lancet 381(9874):1293–1301
Teslovich TM et al (2010) Biological, clinical and population relevance of 95 loci for blood lipids.
Nature 466(7307):707–713
Tietjen I et al (2012) Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families
with extremely high HDL cholesterol. PLoS ONE 7(8):e37437
van Capelleveen JC et al (2014) Novel therapies focused on the high-density lipoprotein particle.
Circ Res 114(1):193–204
van de Bunt M, Gloyn AL (2010) From genetic association to molecular mechanism. Curr Diab
Rep 10(6):452–466
Varbo A et al (2011) TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart
disease in the general population. Arterioscler Thromb Vasc Biol 31(2):451–457
Vergeer M et al (2010) The HDL hypothesis: does high-density lipoprotein protect from athero-
sclerosis? J Lipid Res 51(8):2058–2073
Voight BF et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian
randomisation study. Lancet 380(9841):572–580
Willer CJ et al (2013) Discovery and refinement of loci associated with lipid levels. Nat Genet 45
(11):1274–1283
Wolfrum C et al (2005) Apolipoprotein M is required for prebeta-HDL formation and cholesterol
efflux to HDL and protects against atherosclerosis. Nat Med 11(4):418–422
Xu N, Dahlback B (1999) A novel human apolipoprotein (apoM). J Biol Chem 274(44):31286–
31290
Zhu J et al (2009) Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and
bone morphogenetic protein-1. J Lipid Res 50(7):1330–1339
300 J.A. Kuivenhoven and A.K. Groen
